Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Adverse Events | NCT00679211 | 1 patient in the primary trial was diangosed with Influenza. | Contradiction | [
0,
12
] | [] | {'Clinical Trial ID': 'NCT00679211', 'Intervention': ['INTERVENTION 1: ', ' 6 Months of Follow-up', ' Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.', 'I... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7be7cecb-d265-4098-9969-a40555702573 | |
Single | Adverse Events | NCT00767520 | Both cohorts of the primary trial reported the same number of patients vomiting during the trial. | Entailment | [
0,
5,
13,
18
] | [] | {'Clinical Trial ID': 'NCT00767520', 'Intervention': ['INTERVENTION 1: ', ' Exemestane + Dasatinib', ' Oral dose of exemestane 25 mg + dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Exemestane + Placebo', ' Oral dose of exemestane 25 mg + placebo 100 mg, onc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5b0d3709-7879-4dea-96c3-29178cd9f162 | |
Comparison | Intervention | NCT01420146 | NCT00077376 | the primary trial and the secondary trial both have a control arm, and several test arms. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01420146', 'Intervention': ['INTERVENTION 1: ', ' Zr89-trastuzumab PET/CT', ' Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm'], 'Eligibility': ['Inclusion criteria:', ' All patients selected for this imaging study are patients scheduled to start trastuzumab-... | {'Clinical Trial ID': 'NCT00077376', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab/Ixabepilone/Carboplatin', ' During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cyc... | af70a3a9-d2d0-4d65-81fe-15a1becb5e95 |
Comparison | Eligibility | NCT00372424 | NCT00041067 | Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial. | Entailment | [
0,
1,
2,
3
] | [
3
] | {'Clinical Trial ID': 'NCT00372424', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib + Docetaxel + Trastuzumab', ' Sunitinib 37.5 milligram (mg) capsule orally once daily continuously starting from Day 2 up to Day 15 in each cycle, in schedule 2/1 (2 week on treatment, 1 week off treatment) along with docetaxel 75 m... | {'Clinical Trial ID': 'NCT00041067', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Docetaxel, Vinorelbine and Filgrastim', ' Trastuzumab, docetaxel, vinorelbine and filgrastim', ' docetaxel : 60 mg/m^2 on Day 1 of 21-day cycles', ' vinorelbine : 27.5 mg/m^2 on Days 8 and 15', ' filgrastim : 5 microg/kg/day o... | a378f448-eef0-465a-abc0-8b4dd1156bb5 |
Single | Intervention | NCT01487954 | All patients in the primary trial had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01487954', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Alkaline Water', ' Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' alkaline w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f30182a1-b82a-497c-885c-9bd2e805db62 | |
Single | Results | NCT01106898 | 2% of the primary trial patients had Recurrence-free Survival < 3 years. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01106898', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Chemotherapy With or Without Maintenance Therapy)', ' SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ae87e5a3-fdd8-4003-ae80-4b370cade158 | |
Single | Results | NCT00696072 | Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00696072', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib Plus Letrozole', ' Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years', ' Dasatinib 100 mg + Letrozole 2.5 mg', ' Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9f3062db-16fb-41b8-ac10-f205f66070c8 | |
Single | Results | NCT00022672 | There were no patients in either cohort of the primary trial with a PFS exceeding 6 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00022672', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Anastrozole', ' Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Ex... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a1c5685a-8e6e-4733-aa8b-7040bac1a397 | |
Single | Intervention | NCT00559507 | the primary trial participants are given saracatinib PO for a maximum of 28 days. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00559507', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Enzyme Inhibitor Therapy)', ' Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d58683e2-d276-4184-a8e9-c9df6ffd8047 | |
Comparison | Eligibility | NCT01904903 | NCT01663727 | Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial. | Contradiction | [
3
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18
] | {'Clinical Trial ID': 'NCT01904903', 'Intervention': ['INTERVENTION 1: ', ' HER2 Therapies, Cardiac Medications', ' Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses', ' Oncology intervention - patients will receive one of the three following HER2 targeted therapies at t... | {'Clinical Trial ID': 'NCT01663727', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel+Placebo', ' Participants received paclitaxel 90 mg/m^2 IV on Days 1, 8 and 15 and placebo matched to bevacizumab IV infusion on Days 1 and 15 of a 28 day cycle until progressive disease, treatment limiting toxicity or death.', 'INT... | 28d8f88a-e8cb-40c0-a12b-ef555f83ff59 |
Single | Eligibility | NCT02721147 | Stephanie has been living with her boyfriend for 2 months, she is eligible for the primary trial. | Contradiction | [
0,
5,
6
] | [] | {'Clinical Trial ID': 'NCT02721147', 'Intervention': ['INTERVENTION 1: ', ' Participants Eligible For Enrollment', ' Feasibility is measured before randomization through the percentage of participants enrolled out of the number of individuals approached for the study.'], 'Eligibility': ['Inclusion Criteria:', ' Fema... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0ee4c935-18bd-4807-a2af-041a3d84e125 | |
Single | Eligibility | NCT00371254 | Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer, aswell as not having Dysphagia. | Entailment | [
0,
2,
8,
12
] | [] | {'Clinical Trial ID': 'NCT00371254', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib 100 mg BID', ' Participants were administered an oral dose of 100 mg dasatinib tablet twice daily for a total daily dose (TDD) of 200 mg. Study treatment continued for as long as it was tolerated, or until progressive disease (PD), ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 355fb813-cbe0-44f5-b04a-87813e060d54 | |
Comparison | Adverse Events | NCT00796978 | NCT01276041 | More patients in cohort 1 of the secondary trial suffered from oedema in their limbs, compared to patients in cohort 2 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | {'Clinical Trial ID': 'NCT00796978', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' trastuzumab: Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.', ' laboratory biomarker analysis: Blood... | {'Clinical Trial ID': 'NCT01276041', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.'], 'Eligibility': ['Inclus... | 274d9d2b-9227-4496-a525-d5477b0003ce |
Single | Intervention | NCT00290745 | in the primary trial participants from different ethnicities receive different interventions. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT00290745', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen or Letrozole', ' tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3ab9c66c-06fc-4bc5-b504-d9193efa8701 | |
Single | Eligibility | NCT01252277 | Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial. | Contradiction | [
0,
5
] | [] | {'Clinical Trial ID': 'NCT01252277', 'Intervention': ['INTERVENTION 1: ', ' Lovaza™', ' Lovaza™: 4 capsules daily for 6 months'], 'Eligibility': ['Inclusion Criteria', ' Subjects must be premenopausal and between the ages of 25 and 54 and must have had a menstrual period within the past 12 months. Women who are not ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d39078d9-9bc3-4b91-a012-e95f14813c9a | |
Comparison | Eligibility | NCT00041067 | NCT01273896 | Patients with ER positive, PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
14,
19,
20,
21,
22,
23,
24,
25,
26,
14,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
14,
42,
43,
44,
45,
46,
47,
48,
49,
50,
51,
52,
53,
54... | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42
] | {'Clinical Trial ID': 'NCT00041067', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Docetaxel, Vinorelbine and Filgrastim', ' Trastuzumab, docetaxel, vinorelbine and filgrastim', ' docetaxel : 60 mg/m^2 on Day 1 of 21-day cycles', ' vinorelbine : 27.5 mg/m^2 on Days 8 and 15', ' filgrastim : 5 microg/kg/day o... | {'Clinical Trial ID': 'NCT01273896', 'Intervention': ['INTERVENTION 1: ', ' STA-9090', ' This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.', ' STA-9090: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecut... | 02538194-97ac-4749-9301-83f108927478 |
Comparison | Intervention | NCT01572038 | NCT00826267 | Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients receive 1 of 2 possible drugs. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01572038', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab + Taxane', " Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end, unacceptable toxicity, withdrawal of cons... | {'Clinical Trial ID': 'NCT00826267', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg', ' Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.', 'INTERVENTION 2: ', ' Lapatinib 1500 mg', ' Patients... | 6d9113b4-9d18-4a1b-bc78-cc3ac1150876 |
Single | Intervention | NCT00558103 | All participants in the primary trial are administered with Lapatinib 1500 mg PO QD. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00558103', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo', ' Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD).', 'INTERVENTION 2: ', ' Cohort... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 99599b71-85d7-4c15-8d23-4294732f87cf | |
Single | Eligibility | NCT00768222 | Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial. | Entailment | [
0,
1,
4,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00768222', 'Intervention': ['INTERVENTION 1: ', ' Chinese Silk Suture', ' Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern', 'INTERVENTION 2: ', ' VICRYL* Plus Suture',... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | adbc193f-ffd6-49ce-9acd-7b1675adf0c0 | |
Single | Eligibility | NCT01617668 | Patients must have healthy kidneys, liver and ovaries to participate in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT01617668', 'Intervention': ['INTERVENTION 1: ', ' LCL161 + Paclitaxel (Gene Expression Signature Positive)', ' Patients randomized to the experimental arm for gene expression signature positive received LCL161 1800 mg once weekly + paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of pa... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c476f92a-a450-4e5c-9688-6557ff3d822b | |
Single | Intervention | NCT00900627 | The two groups in the primary trial receive the same drug treatment, but group 2 gets double the dose. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00900627', 'Intervention': ['INTERVENTION 1: ', ' AZD8931 160 mg bd', ' Part A: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle', 'INTERVENTION 2: ', ' AZD8931 120 mg bd', ' Part A: AZD8931 120mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 39d685a4-b179-4687-a273-2a44e675f2c6 | |
Single | Adverse Events | NCT00965523 | The most common adverse events in the primary trial where Infection and Stomatitis, affecting a total of 14 patients. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00965523', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate 1.4 mg/m^2 intravenous infusion given over 2 to 5 minutes on Day 1 and 8 every 21 days.'], 'Eligibility': ['Inclusion criteria:', ' Female patients with histologically or cytologically confirmed breast... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c66963b9-19e0-4c0f-bb65-2fec15e60b8f | |
Comparison | Adverse Events | NCT00559845 | NCT00426556 | In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
14,
15
] | {'Clinical Trial ID': 'NCT00559845', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab', ' FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.', ' FEC: 5-Fluorouracil 600 mg/m^2 i.v. bolus over 15 min; epirubicin 90 mg/m^2 i.v. infusion over 1 hour; cyclophosphamide 600 ... | {'Clinical Trial ID': 'NCT00426556', 'Intervention': ['INTERVENTION 1: ', ' Phase I - RAD001 5mg + PT, Daily', ' Daily dosing schedule of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab', 'INTERVENTION 2: ', ' Phase I - RAD001 10mg + PT, Daily', ' Daily dosing schedule of Everolimus 1... | f541ce25-c43e-496b-98e6-8470fe23f840 |
Single | Results | NCT01224678 | Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01224678', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Patients receive oral placebo once daily for 12 months.', 'INTERVENTION 2: ', ' Vitamin D', ' Patients receive oral vitamin D (2000 IU) once daily for 12 months.'], 'Eligibility': ['Premenopausal women 55 years of age or younger... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dafe9dce-420e-46dc-a8ed-ac2f4c84b49b | |
Comparison | Intervention | NCT00291135 | NCT00291694 | The duration of treatment in the primary trial is half as long as in the secondary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00291135', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole, 2.5 mg daily for six months'], 'Eligibility': ['Inclusion Criteria:', ' evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast', ' on hormone replacement therapy', ' po... | {'Clinical Trial ID': 'NCT00291694', 'Intervention': ['INTERVENTION 1: ', ' Celecoxib', ' Randomized to receive celecoxib daily for 12 months', 'INTERVENTION 2: ', ' Placebo', ' Randomized to receive placebo daily for 12 months'], 'Eligibility': ['Inclusion Criteria:', ' women who have a high risk of breast cancer... | 24d81b18-ce9c-4927-9386-9ebef969a159 |
Single | Eligibility | NCT02756364 | In order to meet the inclusion criteria for the primary trial patients must have had aromatase inhibitor (AI) therapy before study entry, resulting in complete tumor response. | Contradiction | [
0,
9
] | [] | {'Clinical Trial ID': 'NCT02756364', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Fulvestrant 500 mg', ' Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median dur... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0046e113-8ac5-4725-a285-e78b8c26f825 | |
Comparison | Eligibility | NCT00499083 | NCT03045653 | In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer. | Contradiction | [
6,
10,
12
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00499083', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormo... | {'Clinical Trial ID': 'NCT03045653', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' receiving a treatment of tamoxifen 100 mg/d'], 'Eligibility': ['Inclusion Criteria:', ' - Female 18 years, 70 years. ECOG 0-1 with no deterioration over previous 2 weeks Minimum life expectancy 3 months Histological confir... | e90f7748-f4b4-4822-8768-586c3f2f9980 |
Comparison | Eligibility | NCT00429572 | NCT02455453 | post-menopausal patients are excluded from the secondary trial, but eligible for the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00429572', 'Intervention': ['INTERVENTION 1: ', ' Allogeneic Transplantation', ' Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.'], 'Eligibility': ['Inclusion Criteria:', ' Recurrent or residual me... | {'Clinical Trial ID': 'NCT02455453', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic FFNP-PET/CT Scan', ' (2) 18F-FFNP-PET/CT scans', ' First one prior to estradiol challenge test', ' Second one immediately following one day of estradiol challenge test', ' (1) FDG-PET/CT scan at screening', ' The estradiol chal... | fb8f09d6-c393-4943-bc67-fa0f0a6bdd86 |
Single | Eligibility | NCT00932373 | Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial. | Contradiction | [
10,
16
] | [] | {'Clinical Trial ID': 'NCT00932373', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab-MCC-DM1 0.3 mg/kg Every 3 Weeks', ' Trastuzumab-MCC-DM1 0.3 mg/kg administered intravenously (IV) once every 3 weeks', 'INTERVENTION 2: ', ' Trastuzumab-MCC-DM1 0.6 mg/kg Every 3 Weeks', ' Trastuzumab-MCC-DM1 0.6 mg/kg administe... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3c3fb5e3-1994-455a-bae4-6d267c5c89d7 | |
Comparison | Intervention | NCT03573804 | NCT02781051 | Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in the secondary trial patients must use a fitbit. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT03573804', 'Intervention': ['INTERVENTION 1: ', ' Prone to Supine MRI Evaluated by Radiologist A', ' Radiologist A, number of participants successfully segmented', 'INTERVENTION 2: ', ' Prone to Supine MRI Evaluated by Radiologist B', ' Radiologist B, number of participants successfully se... | {'Clinical Trial ID': 'NCT02781051', 'Intervention': ['INTERVENTION 1: ', ' Physical Activity Intervention', ' Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.', ' Print-based education: Subjects were given a copy of Exercise for Health: An Exer... | 2ecd62df-f5ea-417d-8783-2174a6d77087 |
Single | Intervention | NCT01781299 | all subjects in the primary trial must commit to a regular exercise schedule. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01781299', 'Intervention': ['INTERVENTION 1: ', ' AlloDerm RTU', ' Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.', 'AlloDerm RTU', 'INTERVENTION 2: ', ' SurgiMend PRS', ' Participants within this arm will... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b43c02bf-c4b0-495f-b7ba-879f409cb685 | |
Comparison | Eligibility | NCT03136367 | NCT00129935 | Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial. | Entailment | [
0,
1,
6,
7
] | [
18,
38
] | {'Clinical Trial ID': 'NCT03136367', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Option Grid', ' Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.', ' Op... | {'Clinical Trial ID': 'NCT00129935', 'Intervention': ['INTERVENTION 1: ', ' Arm A: EC-T', ' Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycle... | fdff0cf1-a0a2-4516-bdf7-109ac7adb266 |
Single | Adverse Events | NCT00398567 | 80% of patients in the primary trial did not suffer any adverse events. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00398567', 'Intervention': ['INTERVENTION 1: ', ' Part 2 - Expanded MTD Cohort', ' All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg daily by mouth Herceptin: Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6babfc60-5043-4f2b-9605-3e44744265e9 | |
Single | Adverse Events | NCT00274469 | No more than 1% of either cohorts of the primary trial felt nauseous. | Entailment | [
0,
12,
13,
25
] | [] | {'Clinical Trial ID': 'NCT00274469', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', 'Fulvestrant 500 mg', 'INTERVENTION 2: ', ' Anastrozole 1 mg', 'Anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Confirmed hormone receptor positive advanced breast cancer, postmenopausal women', 'Exclusion C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5ca02204-6120-4b02-bf3b-fba94d6fac4f | |
Single | Eligibility | NCT00836186 | Patients cannot be excluded from the primary trial on the basis of gender or ethnicity. | Contradiction | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00836186', 'Intervention': ['INTERVENTION 1: ', ' Radiation Therapy', ' Women with any non-metastatic breast cancer status post lumpectomy to negative margins and who are receiving whole breast irradiation as per standard treatment plan.', ' Radiation therapy: Patients will receive whole br... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 625c2690-ec9e-4ecc-85c0-9b5ca8467848 | |
Single | Adverse Events | NCT00290758 | There was one GU and three GI adverse events recorded in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00290758', 'Intervention': ['INTERVENTION 1: ', ' Arm A (Genistein)', ' Patients receive oral genistein once daily for up to 6 months.', 'INTERVENTION 2: ', ' Arm B (Placebo)', ' Patients receive oral placebo once daily for up to 6 months.'], 'Eligibility': ['Inclusion Criteria:', ' No kn... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c28ad685-4c91-492a-85ab-180f37d9cef5 | |
Single | Eligibility | NCT00829166 | Female patients with Peripheral neuropathy >0 are excluded from the primary trial. | Contradiction | [
9,
12
] | [] | {'Clinical Trial ID': 'NCT00829166', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine', ' Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 52e8d676-1744-4fdb-bab4-a553874329bd | |
Comparison | Intervention | NCT00068601 | NCT01684215 | the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00068601', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy', ' Patients receive cyclophosphamide-containing chemotherapy alone.', ' cyclophosphamide: Part of planned chemotherapy regimen', 'INTERVENTION 2: ', ' Chemotherapy Plus Goserelin', ' Patients receive goserelin subcut... | {'Clinical Trial ID': 'NCT01684215', 'Intervention': ['INTERVENTION 1: ', ' PD-0332991 100 mg: Dose Escalation Cohort', ' In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily co... | beff8878-9405-412d-af3a-0f2720275bf3 |
Single | Results | NCT00089661 | On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00089661', 'Intervention': ['INTERVENTION 1: ', ' Denosumab 60 mg Q6M', '[Not Specified]', 'INTERVENTION 2: ', ' Placebo', '[Not Specified]'], 'Eligibility': ['Histologically or cytologically confirmed adenocarcinoma of the breast', ' Subjects with early stage disease who are estrogen recep... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 96f41881-6ba5-4688-8471-9462fc727919 | |
Single | Adverse Events | NCT02370238 | There were no cases of Intracranial hemorrhage in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02370238', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel+Reparixin (Group 1) - ITT Population', ' paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle.', ' Duration of Treatment: 28-day cycles of combination t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9dbf55d5-6af3-4250-b5cb-97799cdf778a | |
Single | Intervention | NCT00338728 | Participants of the primary trial higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00338728', 'Intervention': ['INTERVENTION 1: ', ' Letrozole and Imatinib Mesylate', ' Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women able to comply with... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e8ce8686-8d5f-4d31-b442-0cb52b7b2bec | |
Single | Results | NCT01118624 | The majority of the primary trial participants achieved CR or PR. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01118624', 'Intervention': ['INTERVENTION 1: ', ' Pralatrexate', ' Study drug 190 mg/m^2 for 2 to 4 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 negative advanced or metastatic breast cancer', ' Disease has become worse after at least 1 prior chemotherapy regimen for advanced o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d72709fd-e94e-4c27-bf56-3f028c0bbd3f | |
Single | Results | NCT00463788 | Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00463788', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin and Cetuximab', ' Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b | |
Single | Intervention | NCT00425854 | Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00425854', 'Intervention': ['INTERVENTION 1: ', ' Cohort B', ' Patients with HER2-negative, ER-positive and/or PgR-positive tumours receiving oral dose of Afatinib 50 mg qd'], 'Eligibility': ['Inclusion criteria:', 'Inclusion Criteria:', ' Female patients age 18 years or older', ' Histolog... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 49f44497-2382-4658-b716-38e66c5c52b7 | |
Single | Adverse Events | NCT00312208 | Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00312208', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)', ' AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4a6dc84a-3afd-4060-b8c5-981895f31099 | |
Single | Adverse Events | NCT02574455 | More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT02574455', 'Intervention': ['INTERVENTION 1: ', ' Sacituzumab Govitecan', ' Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow IV infusion either by gravity or with an infusion pump on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. In... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 11e84dc4-6573-4ad7-b2d9-cfc66b626e1c | |
Single | Adverse Events | NCT00193063 | In the primary trial patient cohort, 3 different types of infections are observed. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00193063', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine/Trastuzumab', ' All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was ad... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f1f2e066-a016-422f-8627-d0e477933352 | |
Single | Eligibility | NCT00295867 | Patients with a Karnofsky status of 94% are eligible for the primary trial. | Entailment | [
13,
16
] | [] | {'Clinical Trial ID': 'NCT00295867', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid', ' Patients who had greater than 4 disseminated tumor cells (DTCs)/mL present following neoadjuvant or adjuvant chemotherapy for early stage breast cancer were treated with 4mg zoledronic acid each month for 24 months.'], 'El... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | efbd87d7-f8ac-42c6-ac9a-e3a35d354885 | |
Single | Results | NCT00558272 | The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00558272', 'Intervention': ['INTERVENTION 1: ', ' AZD0530 175 mg', ' AZD0530 (saracatinib) 175 mg once daily', 'INTERVENTION 2: ', ' Zoledronic Acid 4 mg', ' Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period'], 'Eligibility': ['Inclusion Criteria:', ' Subjects 18 years or older... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a604244f-789f-4c12-8c5a-96c86d1b976e | |
Single | Adverse Events | NCT01565083 | Two different types of tachycardia occurred to patients in cohort 2 of the primary trial. | Entailment | [
12,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01565083', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion', ' Pertuzumab IV infusion at a loading dose of 840 mg on Day 1 of Cycle 1 (cycle length = 21 days), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab IV infusion at a ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2b543cc7-e295-4dc6-ad04-a2e43e9b3d97 | |
Single | Results | NCT01684215 | In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01684215', 'Intervention': ['INTERVENTION 1: ', ' PD-0332991 100 mg: Dose Escalation Cohort', ' In Phase 1-Part 1, participants received single oral dose of PD-0332991 100 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1), followed by PD-0332991 100 mg capsule orally once daily co... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 987b1da5-0276-417d-a659-8e298529ccac | |
Comparison | Eligibility | NCT01176916 | NCT00186121 | postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for the primary trial, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for the secondary trial. | Contradiction | [
0,
3
] | [
0,
2
] | {'Clinical Trial ID': 'NCT01176916', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants received exemestane (Aromasin) tablet 25 mg once daily in this study. They had previously taken tamoxifen for 2 to 3 years and switched to Aromisin in this study for completion of 5 consecutive years of adjuvant ho... | {'Clinical Trial ID': 'NCT00186121', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole + Goserelin', ' Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily.'], 'Eligibility': ['INCLUSION CRITERIA'... | b9e8a0b3-574f-4079-9191-214af99e97a8 |
Comparison | Intervention | NCT01697345 | NCT00513292 | Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01697345', 'Intervention': ['INTERVENTION 1: ', ' FSFI Total Score (Pretest)', ' Administered to participants prior to starting vaginal testosterone therapy.', 'INTERVENTION 2: ', ' FSFI Total Score (Postteset)', ' Testosterone USP micronized powder supplied by Medisca Pharmacy was compoun... | {'Clinical Trial ID': 'NCT00513292', 'Intervention': ['INTERVENTION 1: ', ' FEC-75 Then Paclitaxel/Trastuzumab', ' Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 cour... | 0151d1fa-05c8-45a0-b21e-f08478ea5110 |
Comparison | Adverse Events | NCT01075100 | NCT00290758 | several different mental health issues were observed in the primary trial and the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | {'Clinical Trial ID': 'NCT01075100', 'Intervention': ['INTERVENTION 1: ', ' Triple Negative', ' ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.', 'INTERVENTION 2: ', ' HR Positive', ' ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/H... | {'Clinical Trial ID': 'NCT00290758', 'Intervention': ['INTERVENTION 1: ', ' Arm A (Genistein)', ' Patients receive oral genistein once daily for up to 6 months.', 'INTERVENTION 2: ', ' Arm B (Placebo)', ' Patients receive oral placebo once daily for up to 6 months.'], 'Eligibility': ['Inclusion Criteria:', ' No kn... | b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de |
Single | Eligibility | NCT02027376 | A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for the primary trial. | Contradiction | [
10,
25
] | [] | {'Clinical Trial ID': 'NCT02027376', 'Intervention': ['INTERVENTION 1: ', ' LDE225 (Sonidegib) 400mg in Combination With Docetaxel', ' Cohort 1: Eligible patients were included and treated with docetaxel intravenously (75mg/m2) in every 3 weeks cycles and LDE225 400mg was administered orally QD. Treatment was repeate... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b838a265-99e4-42f0-bd72-b4f72d7eb16e | |
Comparison | Eligibility | NCT00676793 | NCT01931163 | Patients suffering from vomiting are still eligible for both the secondary trial and the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
26
] | {'Clinical Trial ID': 'NCT00676793', 'Intervention': ['INTERVENTION 1: ', ' ECGC and Breast Cancer', ' Single arm for a phase II study of EGCG extract and breast cancer. Subjects are asked to take 4 polyphenol E (200mg) capsules daily with a meal for the duration of the study. Biomarkers are measured at baseline and ... | {'Clinical Trial ID': 'NCT01931163', 'Intervention': ['INTERVENTION 1: ', ' Everolimus Plus Cisplatin', ' Everolimus 10mg by mouth daily for 12 weeks; Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles'], 'Eligibility': ['Inclusion Criteria:', ' Female patients 18 years of age.', ' Cl... | 240e9cb0-3e40-4478-9d2c-fb4ff22e1e21 |
Comparison | Eligibility | NCT00428922 | NCT00499083 | Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial. | Entailment | [
0,
5
] | [
26
] | {'Clinical Trial ID': 'NCT00428922', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Bevacizumab, and Docetaxel', ' Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with evidence of metastatic disease', ' HER... | {'Clinical Trial ID': 'NCT00499083', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormo... | a1644573-fba8-4598-8353-a40d3ef1968c |
Single | Adverse Events | NCT01298193 | More than 15 patients in cohort 1 of the primary trial experienced adverse events. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT01298193', 'Intervention': ['INTERVENTION 1: ', ' Observational Phase (First Cycle):', ' Observational phase (first cycle):', ' Day 0 (Dexamethasone 8mg) Day 1 (5-hydroxytryptamine 3 [5-HT3] antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg).', ' C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ba533122-db9d-49e1-a2d1-936c8fdfdd00 | |
Single | Adverse Events | NCT00274456 | There are a total of 7 cases of Gastritis in the primary trial across both cohorts. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00274456', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 300 mg/m^2 q3w', ' ABI-007 300 mg/m^2 administered once every third week (q3w).', 'INTERVENTION 2: ', ' ABI-007 100 mg/m^2 Weekly', ' ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest'], 'Eligibility': ['Inclusio... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f20cd859-7159-457a-a1cb-56bdb01d521b | |
Single | Adverse Events | NCT00003782 | Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects. | Entailment | [
0,
1,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00003782', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Doxorubicin + Cyclophosphamide, Then Docetaxel', ' Doxorubicin + Cyclophosphamide, then Docetaxel', 'INTERVENTION 2: ', ' Arm 2: Doxorubicin + Docetaxel', ' Doxorubicin + Docetaxel'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Hi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d33df923-6c12-4135-b339-5cefdd240985 | |
Comparison | Adverse Events | NCT00333775 | NCT00201864 | There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT00333775', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel 100 mg/m^2 Plus Placebo', ' Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day ... | {'Clinical Trial ID': 'NCT00201864', 'Intervention': ['INTERVENTION 1: ', ' Exemestane and Fulvestrant', ' Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection', ' Exemestane: 25 mg orally per day', ' Fulvestrant: 250 mg IM starting on Day 8 and then every 28 days.'], 'Eligibility': ['Inc... | 0f49a1ec-ed73-465b-be20-b70fe990b1f0 |
Comparison | Intervention | NCT03196635 | NCT01943916 | the primary trial and the secondary trial are both evaluating imaging techniques. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT03196635', 'Intervention': ['INTERVENTION 1: ', ' All Study Participants, PA Compression Image Sets', ' All image sets (30 patient-assisted compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers.', 'INTERVENTION 2: ', ' All Study Partic... | {'Clinical Trial ID': 'NCT01943916', 'Intervention': ['INTERVENTION 1: ', ' Overall Population', ' Each subject served as her own control, with imaging of each mass by both the test and control modalities. Specificity difference is a single measure for the overall ITD population.'], 'Eligibility': ['Inclusion Criteri... | 7370c10d-f6e7-4153-9649-9d2598ce1ed7 |
Single | Results | NCT00558272 | The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group, with a -73.0 % change from baseline. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00558272', 'Intervention': ['INTERVENTION 1: ', ' AZD0530 175 mg', ' AZD0530 (saracatinib) 175 mg once daily', 'INTERVENTION 2: ', ' Zoledronic Acid 4 mg', ' Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period'], 'Eligibility': ['Inclusion Criteria:', ' Subjects 18 years or older... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3f89537a-479e-4314-b9de-4caf845850fc | |
Comparison | Eligibility | NCT01985971 | NCT03273426 | Patients will have to undergo an MRI scan of the spine for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry. | Contradiction | [
0,
6,
2
] | [
0,
6
] | {'Clinical Trial ID': 'NCT01985971', 'Intervention': ['INTERVENTION 1: ', ' EF5 PET/CT Imaging', 'PET/CT Imaging'], 'Eligibility': ['Inclusion Criteria:', ' Subjects with measurable brain metastases of at least 1 cm in any plane based on anatomic imaging.', ' Subjects with prior resection of brain metastases with pr... | {'Clinical Trial ID': 'NCT03273426', 'Intervention': ['INTERVENTION 1: ', ' Core Needle Biopsy', ' Ultrasound-guided core needle biopsy (14G, 5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.', 'INTERVENTION 2: ', ' Vacuum-assisted Biopsy', ' Vacuum-assisted biopsy (10G, 5 core... | 8e9f417a-dc0f-4c20-9cf7-5f8586c23df2 |
Single | Results | NCT03366428 | 3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT03366428', 'Intervention': ['INTERVENTION 1: ', ' DS-8201a', ' Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Has a pathologically documented unresectable or metast... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8ba451be-606a-4a57-a85e-82b5e5b286fc | |
Comparison | Adverse Events | NCT00721630 | NCT00364611 | the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea. | Contradiction | [
0,
4
] | [
0,
7
] | {'Clinical Trial ID': 'NCT00721630', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Lapatinib', ' The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.', ' capecitabine, lapatinib: Capecitabine 2,000mg twice daily for 7... | {'Clinical Trial ID': 'NCT00364611', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and Bevacizumab', ' Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxici... | 46906361-5133-4db9-b9e5-b9b7f80a8666 |
Single | Eligibility | NCT00121992 | In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-3, N0 and M0 breast cancer. | Entailment | [
12,
13,
14,
15,
19
] | [] | {'Clinical Trial ID': 'NCT00121992', 'Intervention': ['INTERVENTION 1: ', ' Arm A: FAC', ' FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv', ' 5-fluorouracil', ' Doxorubicin', 'Cycl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ab17f223-3f70-4b63-bfc5-1fca5d6ec05d | |
Single | Eligibility | NCT01094184 | A patient who had a Joint injection in the last month would not be eligible for the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT01094184', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab 10 mg/kg Q2W', ' Participants received bevacizumab at a dose of 10 mg/kg Q2W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3320983d-55cb-49f9-9265-ca4e77acf62a | |
Single | Adverse Events | NCT01250379 | None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation. | Entailment | [
0,
5,
7,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT01250379', 'Intervention': ['INTERVENTION 1: ', ' CT Arm', " Participants received a single-agent chemotherapy at the discretion of the investigator according to the standard of care at the investigator's site until disease progression, unacceptable toxicity, participant request for withdraw... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6c57e451-a706-4b32-ae71-254e9d0e04de | |
Single | Intervention | NCT00383500 | the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00383500', 'Intervention': ['INTERVENTION 1: ', ' Flexitouch Device', ' Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)', 'INTERVENTION 2: ', ' Manual Lymphatic Drainage (MLD)', ' Lymphedema management via self-administered m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 73a5f715-6d4c-43f3-ace4-9f1217d3d0c4 | |
Comparison | Adverse Events | NCT00006110 | NCT00464646 | the secondary trial records only gastrointestinal adverse events, whereas the primary trial doesn’t record any GI adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00006110', 'Intervention': ['INTERVENTION 1: ', ' Herceptin Regimen After AC', ' Patients in the adjuvant and neoadjuvant groups after receiving [AC-TP] Chemotherapy (doxorubicin & cyclophosphamide).', 'INTERVENTION 2: ', ' Herceptin Regimen After TP', ' Patients in the adjuvant and neoadj... | {'Clinical Trial ID': 'NCT00464646', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)', 'INTERVENTION 2: ', ' Cohort B', ' Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer'], 'Eligibili... | 83883edd-ea16-4b20-8a97-2a545f957add |
Single | Eligibility | NCT00895414 | Orange juice is banned for patients undertaking the primary trial. | Contradiction | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT00895414', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin Hydrochloride Alone', ' Participants who received doxorubicin hydrochloride alone in either Cycle 1 or Cycle 2.', 'INTERVENTION 2: ', ' Doxorubicin Hydrochloride With Enalapril', ' Participants who received doxorubicin hydrochlo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ad0628ef-be51-4d54-a5c6-7608df258629 | |
Single | Adverse Events | NCT00203502 | Less than 30% of patients in the primary trial experienced at least 1 adverse event. | Contradiction | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00203502', 'Intervention': ['INTERVENTION 1: ', ' Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', ' Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2', ' + Avastin 15 mg/kg', ' Q 3 weeks X 4 cycles', ' Bevacizumab/Avastin: IV 15mg/kg 21 days', ' Cyclophosphamide: 500mg per meter... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 619d88fd-cef5-4f1a-83dc-3cc710c1c93d | |
Single | Intervention | NCT00322374 | Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00322374', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2', ' Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.', 'INTERVENTION 2: ', ' Ixabepilone 30 mg^m2 + E... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 42d6a15e-fa43-4ebc-b627-70f4dd0233f8 | |
Comparison | Intervention | NCT02203565 | NCT00194779 | laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | {'Clinical Trial ID': 'NCT02203565', 'Intervention': ['INTERVENTION 1: ', " Supportive Care (Dakin's Solution, Radiation Therapy)", " Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.", " Dakin's solution: Applied topically", ' radiation therap... | {'Clinical Trial ID': 'NCT00194779', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Therapy, Adjuvant Therapy)', ' See Detailed Description.', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' paclitaxel: Given IV', ' filgrastim: Given SC', ' capecitabine: Given PO', ' meth... | fc60c272-ceeb-47b5-b25b-dca832a2a57e |
Comparison | Adverse Events | NCT00810797 | NCT00828074 | Skin infections were more common in patients in cohort 2 of the secondary trial, than in cohort 1 of the primary trial. | Contradiction | [
0,
5
] | [
13,
21
] | {'Clinical Trial ID': 'NCT00810797', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Exemestane)', ' Patients receive 25mg oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.', ' exemestane: Given orally', ' laboratory biomarker ana... | {'Clinical Trial ID': 'NCT00828074', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level 1 - Vinorelbine at 20mg/m^2', ' Vinorelbine at 20mg/m^2 weekly intravenous (I.V.) on days 1, 8, 15 and sorafenib 200 mg given orally (p.o.) twice daily for 28 days', 'INTERVENTION 2: ', ' Phase I: Dose Level 2 - Vinorelbi... | dfe1236f-ac29-4c1c-a287-6f46abb7703d |
Single | Results | NCT02513472 | Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02513472', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: Eribulin Mesylate + Pembrolizumab', ' Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrol... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b1060434-0f7c-4c4a-bcff-53c3124bb51e | |
Single | Eligibility | NCT00627978 | Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as this would complicate the evaluation of neurologic and other adverse events. | Entailment | [
18,
19
] | [] | {'Clinical Trial ID': 'NCT00627978', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone', ' Participants are treated with Ixabepilone.', ' ixabepilone: ixabepilone 40 mg/m2 Q3w over 3 hours', 'INTERVENTION 2: ', ' Control', ' No treatment with Ixabepilone'], 'Eligibility': ['Inclusion Criteria', ' Ability to unde... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e2862bbf-562f-4c96-abf1-fc9f07655b46 | |
Single | Results | NCT00240071 | At least one participant of the primary trial died in under a 100 days. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00240071', 'Intervention': ['INTERVENTION 1: ', ' Avastin (Bevacizumab) Plus Hormone', ' All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.'], 'Eligibility': ['Inclusion Criteria:', ' Patients mu... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | aed75656-1594-4d99-be42-7097f7926c18 | |
Single | Adverse Events | NCT01961544 | the primary trial reported a combined total of 3 cases of Pericardial effusion, Asthenia and Gastritis in cohort 1. | Contradiction | [
0,
4,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01961544', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants received 1.4 milligrams per meters squared (mg/m^2) eribulin mesylate intravenously over the course of 2 to 5 minutes on Day 1 and Day 8 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteri... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6ce5a9d7-5793-43b0-92ed-980cca3be02b | |
Single | Eligibility | NCT00217399 | To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility. | Contradiction | [
3,
4,
5,
8
] | [] | {'Clinical Trial ID': 'NCT00217399', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib and Anastrozole', ' All patients receive sorafenib and anastrozole.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed breast cancer', ' Metastatic disease', ' Measurable disease, defined as >=1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b2a4f905-c6b5-4977-95de-5aa6424a5bb6 | |
Single | Adverse Events | NCT00591851 | There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial. | Entailment | [
0,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00591851', 'Intervention': ['INTERVENTION 1: ', ' AC Followed by Paclitaxel + Trastuzumab', ' Doxorubicin and Cyclophosphamide (60/600 mg/m2) X 4 followed by Paclitaxel (175 mg/m2) X 4 every 2 weekly with pegfilgrastim (6mg on day 2) + Trastuzumab x 1 year.'], 'Eligibility': ['Inclusion Crit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4 | |
Comparison | Eligibility | NCT00847171 | NCT01764022 | Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial. | Entailment | [
24,
32
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35
] | {'Clinical Trial ID': 'NCT00847171', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine', ' All patients receive weekly Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed adenocarcinoma of t... | {'Clinical Trial ID': 'NCT01764022', 'Intervention': ['INTERVENTION 1: ', ' BCD-022 (CJSC BIOCAD)', ' BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BC... | 4db02d9b-d96e-4ced-947c-71cebcccc933 |
Single | Adverse Events | NCT00201864 | One patient in the primary trial had a WBC count far below normal. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT00201864', 'Intervention': ['INTERVENTION 1: ', ' Exemestane and Fulvestrant', ' Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection', ' Exemestane: 25 mg orally per day', ' Fulvestrant: 250 mg IM starting on Day 8 and then every 28 days.'], 'Eligibility': ['Inc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cfb07772-e485-491c-8ae3-9009e3d04415 | |
Comparison | Intervention | NCT01712009 | NCT00343382 | Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine. | Entailment | [
3,
4,
5
] | [
3,
4,
5
] | {'Clinical Trial ID': 'NCT01712009', 'Intervention': ['INTERVENTION 1: ', ' No Prophylaxis', ' Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim.', 'INTERVENTION 2: ', ' Naproxen 500 mg BID', ' Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to pro... | {'Clinical Trial ID': 'NCT00343382', 'Intervention': ['INTERVENTION 1: ', ' Collective Placebo', ' Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.', 'INTERVENTION 2: ', ' Pilocarpine 2 Times Per Day', ' Patients receive 5mg of... | a283b69c-0f36-4773-a711-9e6088a8ee63 |
Single | Adverse Events | NCT00915018 | The only cases of cardiac problems in the primary trial occurred in cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00915018', 'Intervention': ['INTERVENTION 1: ', ' Neratinib + Paclitaxel', ' Neratinib + Paclitaxel', ' Neratinib: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity,... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8d90d538-3b56-48dd-bd58-007d266c923c | |
Comparison | Intervention | NCT00904033 | NCT03592121 | Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00904033', 'Intervention': ['INTERVENTION 1: ', ' No Exercise', ' Multivitamin Arm + Calcitriol Arm:Calcitriol pill taken once per week', 'INTERVENTION 2: ', ' Exercise', ' Exercise Arm: Exercise consisting of progressive walking and resistance band training', ' Calcitriol+ Exercise Arm: ... | {'Clinical Trial ID': 'NCT03592121', 'Intervention': ['INTERVENTION 1: ', ' AB-101', ' Apply to both nipple/areola regions approximately 1 hour prior to sexual activity', ' AB-101: Apply approximately 1 hour prior to sexual activity', 'INTERVENTION 2: ', ' Placebo', ' Apply to both nipple/areola regions approximat... | fa0fe1a0-2b89-4b78-8fdb-04dee84b4421 |
Single | Intervention | NCT00620373 | the primary trial tests two different breast imaging modalities, namely X-ray and gamma imaging. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00620373', 'Intervention': ['INTERVENTION 1: ', ' Mammography Only', ' For this reporting arm, the interpretation and analysis was done with mammography only.', 'INTERVENTION 2: ', ' Gamma Imaging', ' For this reporting arm, the interpretation and analysis was done with gamma imaging only.... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8502cb9e-e382-41bc-b547-02d2d7beb381 | |
Single | Eligibility | NCT01105312 | Patients with non-measurable diseases are only eligible for phase I of the primary trial. | Entailment | [
5,
6
] | [] | {'Clinical Trial ID': 'NCT01105312', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level One', ' Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered 20 mg LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f6c64bb3-1836-4685-8541-8856f003524b | |
Comparison | Results | NCT00073528 | NCT00191152 | the secondary trial and the primary trial study the Progression Free Survival (PFS) of their participants, however they use different Units of Measure. | Entailment | [
0,
1,
8,
9
] | [
0,
1,
9,
10
] | {'Clinical Trial ID': 'NCT00073528', 'Intervention': ['INTERVENTION 1: ', ' Placebo + Letrozole 2.5 mg', ' Participants received 6 tablets of placebo, identical in appearance to lapatinib tablets, orally daily (approximately at the same time each day), either 1 hour (or more) before breakfast or 1 hour (or more) afte... | {'Clinical Trial ID': 'NCT00191152', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine Plus Docetaxel', ' gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous, day 1 every 21 days.', ' Treatment continues until progression of disease at w... | 79272218-91b9-4331-ba44-6a3709a13f62 |
Comparison | Results | NCT01964924 | NCT00524303 | the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01964924', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Trametinib, Akt Inhibitor GSK2141795)', ' PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progress... | {'Clinical Trial ID': 'NCT00524303', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-we... | 97e3b0d7-3320-4eb5-bc42-5031db87692e |
Single | Results | NCT00708214 | All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00708214', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg With Letrozole', ' Patients received continuous daily dosing with Afatinib 50 mg therapy with letrozole 2.5 mg over 28-day treatment cycles until further disease progression.', 'INTERVENTION 2: ', ' Afatinib 40 mg With Letrozo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 83251670-803e-4fec-a5cf-50f052932752 | |
Single | Adverse Events | NCT01610284 | 1 patient in the primary trial had an abrupt loss of heart function. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01610284', 'Intervention': ['INTERVENTION 1: ', ' BKM120 100mg + Fulvestrant', ' BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.', 'INTERVENTION 2: ', ' Placebo + Fulvestrant', ' BKM120 matching placebo daily and fulvestrant given until progre... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de | |
Comparison | Adverse Events | NCT01256567 | NCT01926886 | The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%). | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01256567', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Docetaxel Combination', ' Docetaxel: Docetaxel administered by intravenous infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.', ' Ramucirumab: Ramucirumab administered as an intravenous infusion at a... | {'Clinical Trial ID': 'NCT01926886', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for t... | e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a |
Single | Eligibility | NCT00093795 | Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial. | Entailment | [
0,
8
] | [] | {'Clinical Trial ID': 'NCT00093795', 'Intervention': ['INTERVENTION 1: ', ' Group 1: TAC X 6', ' Doxorubicin, cyclophosphamide, and docetaxel.', ' Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles', ' Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles', '... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 97812fde-57f3-4299-be34-dd436757adde | |
Comparison | Eligibility | NCT00213980 | NCT02536339 | Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
7
] | {'Clinical Trial ID': 'NCT00213980', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid (ZA)', ' ZA', ' Zoledronic acid (ZA): 4 mg IV over 15 minutes administered once every 12 weeks for 4 cycles', 'INTERVENTION 2: ', ' Observation', ' Observation only for 12 months'], 'Eligibility': ['Inclusion Criteria:', ' ... | {'Clinical Trial ID': 'NCT02536339', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab', ' Participants with CNS metastases secondary to HER2-positive MBC, who had disease progression in the brain following previous treatment with radiotherapy (whole-brain radiation therapy or stereotactic radiosurgery)... | f37774f4-db96-4aa6-b3a1-626953faeecf |
Single | Results | NCT01605396 | The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01605396', 'Intervention': ['INTERVENTION 1: ', ' Ridaforolimus + Dalotuzumab + Exemestane', ' Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles unt... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4fef4cdf-53bf-4239-9d31-4710fd3edc6f | |
Single | Intervention | NCT00181363 | The only difference between the interventions used in the primary trial is the patients position. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00181363', 'Intervention': ['INTERVENTION 1: ', ' Prone', 'Prone position', 'INTERVENTION 2: ', ' Supine', 'Supine position'], 'Eligibility': ['Inclusion Criteria:', ' Patients should have had breast-conserving surgery for breast cancer or DCIS (Ductal Carcinoma in Situ)', ' No indication ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 331affb2-f8e9-4a55-ac4c-62d2ecc4f80b | |
Single | Eligibility | NCT00834678 | Patients must have a white blood cell count above 1,500/mm³ to participate in the primary trial. | Entailment | [
18
] | [] | {'Clinical Trial ID': 'NCT00834678', 'Intervention': ['INTERVENTION 1: ', ' Bendamustine and Erlotinib', ' Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.', ' Participants in dose level II were administered 1... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a577e819-c928-4217-8743-f4809e852919 | |
Comparison | Results | NCT01004172 | NCT00802945 | the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT01004172', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin, Bevacizumab, Trastuzumab (if HER2+)', ' Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.', ' carboplatin: AUC=5 dose given intravenously on day 8 of cycle one an... | {'Clinical Trial ID': 'NCT00802945', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102 14 Day', ' NKTR-102: NKTR-102 given on a q14 day schedule', 'INTERVENTION 2: ', ' NKTR-102 21 Days', ' NKTR-102: NKTR-102 given on a q21 day schedule'], 'Eligibility': ['Inclusion Criteria:', ' Inoperable metastatic or locally adv... | bd073d05-3ba2-4898-9d86-a51951a7ad1f |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.